FDA approves Lilly-Boehringer Ingelheim diabetes drug

Jentadueto approved for Type 2 diabetes

INDIANAPOLIS — The Food and Drug Administration has approved a new treatment for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim, the drug makers said.

The FDA approved Jentadueto (linagliptin and metformin) tablets, designed to be taken twice daily. The approval marks the second since the two companies announced their collaboration to develop diabetes drugs in January 2011; the first drug approved under the Lilly-BI partnership was Tradjenta (linagliptin), approved in May 2011.

The approval of Jentadueto comes days after the FDA approved Amylin Pharmaceuticals' Bydureon (exenatide), which Amylin had developed under a partnership with Lilly that the two companies terminated in November 2011 after Lilly entered its current partnership with BI. Bydureon is a once-weekly formulation of the injected Type 2 diabetes drug Byetta.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.